The biotech has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its spinocerebellar ...

Shares of US clinical-stage biotech Biohaven (NYSE: BHVN) rose 9.6% to $21.74 yesterday, after it announced an agreement with ...

Oberland Capital Management is pumping some new life into Biohaven, striking a unique investment deal worth up to $600 ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

Biohaven Ltd. on Monday announced that New York-based Oberland Capital has agreed to invest up to $600 million in the New ...

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

A genetic signature including four genes in gastric cancer is linked to an increase in recurrence and mortality.

Early identification of individuals at a high risk for MASLD could “profoundly transform” intervention strategies, experts ...

Biohaven meanwhile recorded Nurtec ODT sales of $462 million in 2021, a performance that prompted Pfizer to stump up $500 million upfront for rights to the drug outside the US last November.

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of ...